Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 15,200 shares, an increase of 19.7% from the December 15th total of 12,700 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 13,300 shares, the short-interest ratio is currently 1.1 days.

Several equities research analysts have commented on MIST shares. Zacks Investment Research lowered Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday. Cowen reiterated a “buy” rating and set a $32.00 price objective on shares of Milestone Pharmaceuticals in a research note on Thursday, November 14th. Finally, ValuEngine upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $30.10.

In other news, major shareholder Rtw Investments, Lp acquired 400,000 shares of the business’s stock in a transaction on Wednesday, November 20th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $6,400,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Holdings A/S Novo sold 240,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $16.00, for a total value of $3,840,000.00. Following the sale, the insider now owns 2,434,470 shares of the company’s stock, valued at $38,951,520. The disclosure for this sale can be found here. Over the last quarter, insiders have acquired 692,771 shares of company stock valued at $11,323,920.

Hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new stake in shares of Milestone Pharmaceuticals in the second quarter valued at approximately $51,000. Millennium Management LLC lifted its holdings in Milestone Pharmaceuticals by 76.3% in the third quarter. Millennium Management LLC now owns 23,704 shares of the company’s stock valued at $410,000 after acquiring an additional 10,255 shares during the last quarter. Pentwater Capital Management LP acquired a new position in Milestone Pharmaceuticals in the second quarter valued at approximately $679,000. VHCP Management II LLC acquired a new position in Milestone Pharmaceuticals in the second quarter valued at approximately $4,033,000. Finally, Zimmer Partners LP acquired a new position in Milestone Pharmaceuticals in the second quarter valued at approximately $4,344,000. Institutional investors and hedge funds own 53.37% of the company’s stock.

NASDAQ:MIST opened at $17.84 on Wednesday. Milestone Pharmaceuticals has a 12 month low of $12.36 and a 12 month high of $27.95. The stock has a 50 day moving average of $16.42 and a two-hundred day moving average of $18.84.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, November 13th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.04). Equities research analysts forecast that Milestone Pharmaceuticals will post -3.27 earnings per share for the current year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

See Also: What are some reasons analysts would give stocks a buy rating?

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.